---
title: "Piper Sandler Sticks to Its Buy Rating for Axsome Therapeutics (AXSM)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/299441874.md"
description: "Piper Sandler analyst David Amsellem reiterated a Buy rating on Axsome Therapeutics today and set a price target of $258.00. According to TipRanks, Amsellem is a 5-star analyst with an average return of 15.2% and a 60.12% success rate. Amsellem covers the Healthcare sector, focusing on stocks such as AbbVie, Amgen, and Teva Pharmaceutical. In a report released today, RBC Capital also maintained a Buy rating on the stock with a $297.00 price target."
datetime: "2026-09-18T11:26:34.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/299441874.md)
  - [en](https://longbridge.com/en/news/299441874.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/299441874.md)
generator: "portal-rs"
---

# Piper Sandler Sticks to Its Buy Rating for Axsome Therapeutics (AXSM)

Piper Sandler analyst David Amsellem reiterated a Buy rating on Axsome Therapeutics today and set a price target of $258.00.

According to TipRanks, Amsellem is a 5-star analyst with an average return of 15.2% and a 60.12% success rate. Amsellem covers the Healthcare sector, focusing on stocks such as AbbVie, Amgen, and Teva Pharmaceutical.

In a report released today, RBC Capital also maintained a Buy rating on the stock with a $297.00 price target.

### Related Stocks

- [AXSM.US](https://longbridge.com/en/quote/AXSM.US.md)
- [PIPR.US](https://longbridge.com/en/quote/PIPR.US.md)
- [ABBV.US](https://longbridge.com/en/quote/ABBV.US.md)
- [AMGN.US](https://longbridge.com/en/quote/AMGN.US.md)
- [TEVA.US](https://longbridge.com/en/quote/TEVA.US.md)
- [RY.US](https://longbridge.com/en/quote/RY.US.md)

## Related News & Research

- [Is Axsome Therapeutics a Buy on the Dip?](https://longbridge.com/en/news/299414581.md)
- [Axsome Therapeutics (AXSM) Unveils New Depression And Alzheimer’s Agitation Data At Psych Congress 2026](https://longbridge.com/en/news/299429695.md)
- [Truist Securities maintains Buy rating on Axsome Therapeutics, $285 price target](https://longbridge.com/en/news/299921112.md)
- [Marvell Now Sees as Much as $90 Billion in Annual Sales by Fiscal 2031. Here's Why It's a Chip Stock to Buy.](https://longbridge.com/en/news/301114413.md)
- [Marvell just impressed Wall Street with 'good numbers plus a better story'](https://longbridge.com/en/news/301066509.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**